Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly neutralizing antibodies (bNAbs) 1,2 . However, even the best bNAbs neutralize 10-50% of HIV-1 isolates inefficiently (80% inhibitory concentration (IC 80 ) . 5 mg ml 21 ), suggesting that high concentrations of these antibodies would be necessary to achieve general protection 3-6 . Here we show that eCD4-Ig, a fusion of CD4-Ig with a small CCR5-mimetic sulfopeptide, binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is more potent than the best bNAbs (geometric mean half-maximum inhibitory concentration (IC 50 ) , 0.05 mg ml 21 ). Because eCD4-Ig binds only conserved regions of Env, it is also much broader than any bNAb. For example, eCD4-Ig efficiently neutralized 100% of a diverse panel of neutralizationresistant HIV-1, HIV-2 and simian immunodeficiency virus isolates, including a comprehensive set of isolates resistant to the CD4-binding site bNAbs VRC01, NIH45-46 and 3BNC117. Rhesus macaques inoculated with an AAV vector stably expressed 17-77 mg ml 21 of fully functional rhesus eCD4-Ig for more than 40 weeks, and these macaques were protected from several infectious challenges with SHIV-AD8. Rhesus eCD4-Ig was also markedly less immunogenic than rhesus forms of four well-characterized bNAbs. Our data suggest that AAVdelivered eCD4-Ig can function like an effective HIV-1 vaccine.
coreceptor-binding sites [9] [10] [11] . The immunoadhesin form of CD4, CD4-Ig, has been extensively studied as a therapeutic. It neutralizes most isolates, irreversibly inactivates Env, and is demonstrated safe for use in humans [12] [13] [14] [15] . However, its affinity for Env is lower than those of bNAbs 16 , and its potency is further compromised by its parallel ability to promote infection 17 . Mimetics of the primary HIV-1 coreceptor CCR5, in particular peptides based on its tyrosine-sulfated amino terminus, have also been characterized 18, 19 . These sulfopeptides bind Env specifically but with low affinity in the absence of CD4, in part because they include hydrophobic residues and O-linked glycosylation that impede their association with Env 18, 20 . CCR5mim1, a 15-amino-acid sulfopeptide derived from the HIV-1 neutralizing antibody E51 (ref. 21) , lacks these interfering elements ( Fig. 1a ) and binds Env with higher affinity than CCR5-based peptides 20, 22 . Reflecting the conservation of the sulfotyrosine-binding pockets of Env 9,10 , CCR5mim1 binds both CCR5-and CXCR4-dependent Env proteins from all HIV-1 clades 20, 22 .
We reasoned that a fusion of CD4-Ig and CCR5mim1 would bind Env cooperatively and with higher avidity than either molecule alone. Accordingly, three fusion proteins were generated (sequences in Extended Data Fig. 1 ). CCR5mim1 was inserted at either the CD4-Ig amino terminus (fusion 1), between the CD4 and Fc domain (fusion 2), or at the CD4-Ig carboxy terminus (fusion 3, renamed eCD4-Ig). All three CD4-Ig variants neutralized CCR5-and CXCR4-dependent isolates more efficiently than did CD4-Ig, with eCD4-Ig consistently the most potent (Extended Data Fig. 2a, b ). eCD4-Ig neutralized a wider panel of HIV-1 isolates and SIVmac316 with 10-to 100-fold lower IC 50 values than CD4-Ig ( Fig. 1b ). Improved neutralization of SIVmac316 is consistent with conservation of the sulfotyrosine-binding pockets of Env 9,10 , and a first indication of the exceptional breadth of eCD4-Ig.
To understand better the markedly greater potency of eCD4-Ig relative to CD4-Ig, we compared their abilities to bind cell-surface-expressed Env trimers ( Fig. 1c) . At low concentrations, eCD4-Ig bound these trimers more efficiently than did CD4-Ig. Surprisingly, eCD4-Ig saturated trimer-expressing cells with approximately one-third less bound protein than CD4-Ig, suggesting that the sulfopeptides of eCD4-Ig made some CD4-binding sites inaccessible. eCD4-Ig also less efficiently promoted HIV-1 infection of CCR5-positive, CD4-negative cells than CD4-Ig ( Fig. 1d ), presumably because its sulfopeptides blocked virion access to cell-surface CCR5. Heterodimers of CD4-Ig and eCD4-Ig 23 neutralized less potently than eCD4-Ig ( Fig. 1e and Extended Data Fig. 2c-e ), indicating that both eCD4-Ig sulfopeptides engage the Env trimer, consistent with a model of eCD4-Ig bound to Env (Extended Data Fig. 3 ) and previous studies of CCR5mim1 (ref. 24) . Thus, the markedly greater potency of eCD4-Ig relative to CD4-Ig is due in part to the higher avidity with which it binds Env and to its decreased ability to promote infection.
We next assessed eCD4-Ig under more physiological conditions. We observed that eCD4-Ig, but not CD4-Ig, halted replication of infectious viruses in human peripheral blood mononuclear cells (PBMC) at concentrations as low as 125 ng ml 21 (Extended Data Fig. 1f, g) . We administered sufficient eCD4-Ig to humanized NOD/SCID/Il2rg 2/2 (NSG) mice to maintain serum concentrations of 2-4 mg ml 21 at the time of challenge. Five eCD4-Ig-treated mice and six control mice were challenged intravenously with 5 3 10 4 infectious units of HIV-1 NL4-3 . Five out of six control mice, but no eCD4-Ig-inoculated mice, were infected ( Fig. 1f and Extended Data Fig. 2h ). Five weeks later, three eCD4-Igtreated mice and the uninfected control mouse were rechallenged. Again, no eCD4-Ig-treated mouse was infected, whereas the control mouse became infected.
We then characterized the ability of eCD4-Ig to neutralize a diverse panel of neutralization-resistant tier 2 and 3 viruses 25 (Extended Data Figs 4a and 5a). In parallel, we assayed three additional eCD4-Ig variants. In the first, eCD4-Ig mim2 , CCR5mim1 was replaced by CCR5mim2, which differs from CCR5mim1 by a single Ala to Tyr substitution 22 . We also introduced a previously characterized Gln 40 to Ala mutation into the CD4 domain 1 of eCD4-Ig (eCD4-Ig Q40A ) 16 . Both mutations were combined in a final variant (eCD4-Ig Q40A,mim2 ). eCD4-Ig and these variants substantially outperformed CD4-Ig for every virus in the panel, typically improving neutralization potency by 20-to .200-fold. Underscoring its breadth, eCD4-Ig neutralized SIVmac251 33 times more efficiently than CD4-Ig. In general, the more neutralization-resistant a virus, the better eCD4-Ig and its variants performed relative to CD4-Ig. In most cases, replacement of CCR5mim1 with CCR5mim2 modestly improved neutralization. Similarly, the Gln40Ala mutation also improved neutralization of most HIV-1 isolates, but not of SIVmac251.
We compared eCD4-Ig, eCD4-Ig mim2 and eCD4-Ig Q40A,mim2 with a panel of 12 antibodies and inhibitors using three additional HIV-1 isolates ( Fig. 2a and Extended Data Fig. 6a, b ). eCD4-Ig and its variants neutralized the SG3 and YU2 isolates more efficiently than any of these inhibitors. Five bNAbs neutralized JR-CSF more efficiently than any eCD4-Ig variant, but four of these could not neutralize SG3. All eCD4-Ig variants neutralized these isolates with IC 50 values less than 0.3 mg ml 21 , which is more efficiently than CD4-Ig, the tetrameric CD4-Ig variant 14) , or the antibodies 2G12, 4E10 and VRC01. eCD4-Ig and its variants, but not three CD4-binding site bNAbs, neutralized the neutralization-resistant SIVmac239 as well as HIV-2 strain ST ( Fig. 2b and Extended Data Fig. 6c ). As observed with SIVmac251, the Gln40Ala variant was less efficient at neutralizing SIVmac239 and HIV-2. The potency of these eCD4-Ig variants was also reflected in their abilities to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). eCD4-Ig, eCD4-Ig mim2 and eCD4-Ig Q40A,mim2 each facilitated 30-40 times more killing of infected cells by CD16 1 natural killer cells 26 than did CD4-Ig or the antibody IgGb12 ( Fig. 2c ). Thus the C-terminal modification of eCD4-Ig did not interfere with the ADCC effector function of its Fc domain.
We further evaluated eCD4-Ig, eCD4-Ig mim2 , eCD4-Ig Q40A,mim2 and the bNAb NIH45-46 using nearly every isolate reported to be resistant to either of the CD4bs antibodies NIH45-46 or 3BNC117 (Extended Data Figs 4b and 5b). Both eCD4-Ig variants efficiently neutralized all 38 resistant isolates assayed with IC 50 values ranging from ,0.001 to 1.453 mg ml 21 . By contrast, 26 isolates in this panel were confirmed to be resistant to NIH45-46. Previous reports found 29 and 18 isolates to be resistant to 3BCN117 and VRC01, respectively 4,6 . Figure 3 and Extended Data Fig. 7 summarize the neutralization studies compiled from the experiments in Figs 1 and 2 and Extended Data Figs 4-6, and from previous studies of VRC01 and 3BNC117 against the same isolates 4 . They show that the geometric mean IC 50 and IC 80 values of eCD4-Ig and its variants are less than 0.05 mg ml 21 (500 pM) and 0.2 mg ml 21 (2 nM), respectively, roughly 3-4 times lower than those of VRC01, NIH45-46 or 3BNC117. Importantly, our lead eCD4-Ig variant, eCD4-Ig mim2 , neutralized 100% of the isolates assayed at concentrations (IC 50 , 1.5 mg ml 21 ; IC 80 , 5.2 mg ml 21 ) that are probably sustainable in humans. CD4 domains 1 and 2 (blue) fused to the human IgG1 Fc domain (grey). In eCD4-Ig, the sulfopeptide CCR5mim1 (red) is fused to the C terminus of CD4-Ig. The sequence of the CCR5 N terminus is provided for comparison. Common residues, including four CCR5 sulfotyrosines, are shown in red. CCR5mim1 Ala 4 (blue) is substituted with Tyr in CCR5mim2, described below. b, HIV-1 pseudotyped with the Env proteins of the indicated HIV-1 or SIV isolates was incubated with GHOST-CCR5 cells and varying concentrations of CD4-Ig (red) or eCD4-Ig (blue). Infection was measured as green fluorescent protein (GFP)-expression by flow cytometry. Errors of replicates are less than 20% of indicated values but not indicated for clarity. c, 293T cells transfected to express 89.6 or ADA Env proteins were incubated with the indicated concentrations of CD4-Ig (red), eCD4-Ig (blue) or IgG (grey) and analysed by flow cytometry. d, HIV-1 expressing luciferase and pseudotyped with the Env proteins of the indicated isolates was incubated with Cf2Th-CCR5 cells in the presence of varying concentrations of CD4-Ig (red) or eCD4-Ig (blue). Experiment was controlled with HIV-1 pseudotyped with the VSV-G protein (grey). Infection normalized to the maximum value observed for each pseudovirus. e, HIV-1 pseudotyped with the 89.6 Env was incubated with TZM-bl cells and varying concentration of CD4-Ig (red), eCD4-Ig (blue) or a CD4-Ig/eCD4-Ig heterodimer (green). Similar experiments using additional Env proteins are shown in Extended Data Fig. 2c , d. f, Infection curves of humanized NSG mice with 2-4 mg ml 21 of serum eCD4-Ig at time of HIV-1 NL4-3 challenges (blue line, n 5 5), or mock treated (red line, n 5 6) are shown. Three uninfected eCD4-Ig treated mice and the sole uninfected mock treated mouse were rechallenged 5 weeks after the first challenge. Significant protection (P 5 0.002; Mantel-Cox test) was observed in the eCD4-Ig-treated group. Viral load measurements are shown in Extended Data Fig. 2h . Experiments in b-e were performed at least twice with each indicated isolate with similar results. Errors bars denote one s.e.m. of duplicates.
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Finally, using a rhesus macaque form of eCD4-Ig mim2 , we investigated whether AAV-delivered eCD4-Ig could function like an HIV-1 vaccine. To minimize potential adverse reactions, the Fc domain of rhesus IgG2, which binds Fc receptors and complement less efficiently than IgG1, was used. We also introduced an Ile39Asn mutation into the CD4 domain 27 to correct partially the lower affinity of rhesus CD4 for most HIV-1 isolates (Extended Data Fig. 8a, b ). The gene for the resulting construct, rh-eCD4-IgG2 I39N,mim2 (described hereafter as rh-eCD4-Ig), was cloned into a single-stranded AAV2 vector (AAV-rh-eCD4-Ig; Extended Data Fig. 8c ). A total of 2.5 3 10 13 AAV1-encapsidated particles delivering this vector were administered into the quadriceps of four four-year-old male Indian-origin rhesus macaques. To promote rh-eCD4-Ig sulfation, a separate single-stranded AAV vector expressing rhesus tyrosine-protein sulfotransferase 2 (AAV-rh-TPST2; Extended Data Fig. 8c ) was co-administered with AAV-rh-eCD4-Ig at a 1:4 ratio. No adverse reactions were observed in any of the AAV-rh-eCD4-Ig-inoculated macaques. These macaques and four age-and gendermatched controls were challenged intravenously with increasing doses of SHIV-AD8 ( Fig. 4a, b ). Sixteen weeks after AAV inoculation, two control macaques became infected following challenge with 200 pg p27. A subsequent 400 pg challenge infected a third control animal, and, after resisting an additional 400 pg challenge, the final control was infected with 800 pg, 34 weeks from the date of AAV inoculation. None of these challenges infected AAV-rh-eCD4-Ig-inoculated macaques, indicating that eCD4-Ig protected them from four doses capable of infecting control animals.
Measured rh-eCD4-Ig titres in the serum stabilized to between 17 and 77 mg ml 21 over the last 10 weeks of the 40-week study period ( Fig. 4c ). Two macaques expressed less than 20 mg ml 21 at the time of the final 800 pg challenge, suggesting that this concentration could prevent many otherwise infectious exposures in humans. Sera from inoculated macaques neutralized HIV-1 as efficiently as laboratory-prepared rh-eCD4-Ig mixed with pre-inoculation sera ( Fig. 4d and Extended Data Fig. 8d ), antibodies. a, HIV-1 pseudotyped with the Env proteins of the indicated isolates were incubated with TZM-bl cells and varying concentrations of the indicated entry inhibitors, and the resulting IC 50 values are plotted. IC 90 values and standard errors are presented in Extended Data Fig. 6a, b . b, Experiments similar to those in a except that HIV-1 pseudotyped with the SIVmac239 Env was incubated with varying concentrations of CD4-Ig, eCD4-Ig variants or CD4bs antibodies. Extended Data Fig. 6c shows a similar study using the HIV-2 ST Env. Errors bars denote one s.e.m. of triplicates. c, ADCC activity was assessed using CEM.NKR-CCR5 target cells incubated with infectious HIV-1 NL4-3, SIVmac239 or SHIV KB9 for 4 days. Cells were then incubated with KHYG-1 NK effector cells 26 
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indicating that the eCD4-Ig was efficiently sulfated and fully active in vivo.
We also compared macaque humoral responses to expressed rh-eCD4-Ig and to four AAV-expressed bNAbs inoculated for a separate study. 3BNC117, NIH45-45, 10-1074 and PGT121, each bearing rhesus IgG2 and light-chain constant domains, elicited markedly higher endogenous antibody responses than did rh-eCD4-Ig, consistent with their high levels of somatic hypermutation (Fig. 4e ). To investigate the target of the anti-rh-eCD4-Ig responses, we increased the sensitivity of our assay and compared longitudinally the reactivity of inoculated rhesus sera to a series of antigens. rh-eCD4-Ig ( Fig. 4f ) and rh-CD4-Ig (without the CCR5mim2 sulfopeptide; Fig. 4g ) were recognized by rhesus sera with nearly the same reactivity, whereas CCR5mim2 fused to a human IgG1 Fc domain was not ( Fig. 4h ), indicating that the sulfopeptide was not immunogenic. Rhesus CD4 domains 1 and 2 fused to a human IgG1 Fc was much less reactive than the same CD4 domains fused to the rhesus IgG2 Fc, without or with the Ile39Asn mutation (Extended Data Fig. 8e, f) , whereas an unrelated construct bearing the rhesus IgG2 Fc domain showed no reactivity (Extended Data Fig. 8g ), suggesting that a neoepitope formed by the rhesus CD4 and Fc domains was recognized by most anti-rh-eCD4-Ig antibodies. Thus eCD4-Ig is less immunogenic than bNAbs, and can be expressed for at least 40 weeks at concentrations that are well tolerated and protective against several robust SHIV-AD8 challenges.
A key question is whether eCD4-Ig or a similar construct could be used to prevent new HIV-1 infections in a population, and whether it might do so more effectively than a bNAb. We show that AAV-delivered rhesus eCD4-Ig protected all inoculated macaques from multiple infectious doses that are probably higher than those present in most human transmission events, although we have not yet tested protection from mucosal challenges. Protection lasted at least 34 weeks after inoculation (Fig. 4b) , and other studies indicate that these protective titres can be sustained for several years 2 . Previous studies of CD4-Ig indicate that it is safe when passively administered 12, 14 , and in particular it does not engage MHC II or otherwise interfere with immune function 13 , although further safety studies of eCD4-Ig are warranted. eCD4-Ig has fewer non-self B-and T-cell epitopes than heavily hypermutated bNAbs, and thus elicits fewer endogenous antibodies that can impair its expression and activity ( Fig. 4e ). Its most prominent non-self element is its sulfopeptide, which did not elicit any measurable antibody responses ( Fig. 4f-h) . However, the clearest advantage of eCD4-Ig over bNAbs is its potency and its unmatched breadth ( Fig. 3 and Extended Data Figs 4-7). The breadth of eCD4-Ig arises from the necessary conservation of its binding sites on Env, suggesting that emergence of eCD4-Ig escape variants in a population is less likely than with bNAbs. Moreover, any virus that does bypass prophylaxis is likely to bind CD4 and CCR5 less efficiently in the continued presence of eCD4-Ig, and may therefore be less efficiently retransmitted. Its potency suggests that relatively lower concentrations of eCD4-Ig will be sufficient to protect against most circulating viruses, a feature that may be critical to its use with AAV in humans. Although there are remaining challenges, these observations suggest that AAV-expressed eCD4-Ig could provide effective, long-term and near universal protection from HIV-1.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. a, Infection analysis comparing four male Indian-origin rhesus macaques inoculated intramuscularly with 2 3 10 13 AAV particles delivering rh-eCD4-Ig (blue) and four age-and gender-matched controls (red). At 8, 11, 16, 20, 26 and 34 weeks after inoculation, macaques were challenged with the indicated p27 titres of SHIV-AD8. Significant protection (P 5 0.006; Mantel-Cox test) was observed in the AAV-rh-eCD4-Ig-treated group. b, Viral loads of inoculated (blue) and control (red) macaques are shown, with the time and titre of challenge indicated above the graph. c, Concentrations of rh-eCD4-Ig in the sera of inoculated macaques were measured by ELISA to week 40 after inoculation. d, The neutralizing potency of macaque sera obtained 4 weeks after AAV-inoculation was compared to pre-inoculation sera (pre-sera), and presera mixed with laboratory-produced rh-eCD4-Ig, as in Fig. 2b . e, Antitransgene antibody responses in AAV-rh-eCD4-Ig-inoculated macaques were compared to those in macaques inoculated with AAV expressing the indicated bNAbs bearing constant regions of rhesus IgG2. Sera from 4 weeks after inoculation were analysed. Plates were coated with equivalent amounts of rh-eCD4-Ig or rhesus forms of bNAbs and incubated with sera and anti-rhesus lambda chain (left) or kappa chain (right) antibody conjugated to horseradish peroxidase. Note that 3BNC117 and NIH45-46 bear a kappa light chain, whereas PGT121 and 10-1074 bear a lambda light chain, so that only host antibody responses were detected. Values indicate absorbance at 450 nM. P values (Student's two-tailed t-test) are indicated above the figures. f, The sensitivity of the assay in e was increased to measure longitudinally the antirh-eCD4-Ig activity in the sera of inoculated macaques. Both anti-kappa and anti-lambda secondary antibodies were used. Values are scaled for comparison to values in e. g, h, The same assay as in f except that responses to rh-CD4-Ig, lacking CCR5mim2 (g) or to CCR5mim2 fused to a human IgG1 Fc domain (h) were measured. Experiments in c-h were performed at least twice with similar results. Errors bars denote one s.e.m. of duplicates.
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METHODS Plasmids and cells. Plasmid expressing CD4-Ig was previously described 20 . Fusion constructs were created by adding sequences encoding CCR5mim1 and tetra-glycine linker to N terminus (fusion1) or between domain 2 and human Fc (fusion2) of CD4-Ig by inverse PCR. eCD4-Ig (fusion3) and eCD4-Ig mim2 were created by adding sequence encoding a tetra-glycine linker and CCR5mim1 or CCR5mim2, respectively, to the C terminus of CD4-Ig by inverse PCR. The Gln 40 to Ala mutation was introduced in eCD4-Ig and eCD4-Ig mim2 by Quickchange PCR. The eCD4-Ig/ CD4-Ig heterodimer was generated as previously described 23 and analysed by SDS-PAGE under reducing and non-reducing conditions. rh-eCD4-Ig, consisting of rhesus CD4 domains 1 and 2 bearing an Ile39Asn mutation, rhesus IgG2 Fc and CCR5mim2, was synthesized and cloned into a previously described single-stranded AAV plasmid 2 . AAV expression plasmids for HIV-1 antibodies were created by synthesizing the variable heavy and light chains of 3BNC117, NIH45-46, PGT121 and 10-1074 with the rhesus heavy and light constant regions, and cloning these genes into a previously described ssAAV plasmid 2 . The following reagent was obtained through the NIH AIDS Reagent Program (Division of AIDS, NIAID, NIH): CMVR-VRC01-H, CMVR-VRC01-L, from J. Mascola 28,29 , pNL4-3.Luc.R-.E-from N. Landeau 30, 31 , TZM-bl cells from J. C. Kappes, X. Wu and Tranzyme Inc 32-36 , SF162 gp160 from L. Stamatatos and C. Cheng-Mayer 37 , and GHOST-CCR5 and -CXCR4cells from V. KewalRamani and D. Littman. Human embryonic kidney HEK293T cells were obtained from ATCC. Cf2Th-CD4 1 .CCR5 1 and CfTh-CCR5 1 cells were a gift from H. Choe. No testing for mycoplasma contamination was performed in any cell line after their receipt from these contributors. The variable heavy and light chains of IgG-b12, NIH45-46, 3BNC117, 10-1074 and PGT121 were cloned into the CMVR-VRC01-H and -L plasmids. Plasmids encoding TPST-2 or the envelope glycoproteins pNL4-3Denv, 89.6, ADA, SG3, SA32, YU2, JRFL, KB9, VSV-G, HIV-2 ST, SIVmac239, SIVmac316 and replicative 89.6 or SG3 viruses were previously described 20, 21, [38] [39] [40] . Purification of antibodies, CD4-Ig and eCD4-Ig variants. Production of CD4-Ig, eCD4-Ig variants and antibodies was performed as previously described 41 . In brief, HEK293T cells in 140 mm plates were transfected with 25 mg per plate at 50% confluency by the calcium phosphate transfection method. Plasmids encoding sulfated proteins were cotransfected with a plasmid encoding human tyrosine protein sulfotranserase 2 (TPST2). At 12 h after transfection, 10% FBS-DMEM media was replaced with serum-free 293 Freestyle media (Invitrogen). Media was collected after 48 h, debris was cleared by centrifugation for 10 min at 1,500g and filtered using 0.45-mm filter flasks (Millipore). Complete protease inhibitor cocktail (Roche) was added to the filtered supernatants. A 500-ml bed volume of Protein A sepharose beads (GE Healthcare) was added and agitated at 4 uC overnight. The bead-media mixture was collected by gravity flow column (Biorad) and was washed with 30 ml PBS (Lonza) plus 0.5 M NaCl (0.65 M NaCl final) followed by 10 ml PBS. Protein was eluted with 3 M MgCl 2 in PBS. Buffer was exchanged for PBS and protein was concentrated to 1 mg ml 21 by Ultrafiltration (Amicon Ultra) at 4,000g. Flow cytometry analysis of CD4-Ig and eCD4-Ig binding to cell-expressed envelope glycoprotein. HEK293T cells were transfected with plasmids expressing envelope glycoprotein lacking cytoplasmic residues 732 to 876 (HXBc2 numbering) together with plasmid encoding the tat protein. Transfection medium was replaced after an overnight incubation and cells were collected 48 h after transfection. Collected cells were washed twice in flow cytometry buffer (PBS with 2% goat serum, 0.01% sodium azide). Cells were incubated with CD4-Ig or eCD4-Ig on ice for 1 h and then washed twice with flow cytometry buffer. A secondary antibody recognizing human Fc (Jackson Immuno Research) was added to the cells for 30 min. Cells were washed twice with flow cytometry buffer, twice with PBS, and resuspended in 1% paraformaldehyde solution. Binding was analysed with an Accuri C6 Flow Cytometer (BD Biosciences) and data analysed with the C6 Software (BD Biosciences). Viral entry enhancement assay. HIV-1 pseudovirus expressing firefly luciferase was pre-incubated with titrated amounts of CD4-Ig or eCD4-Ig variants in DMEM (10% FBS) for 1 h at 37 uC. CD4-negative Cf2Th-CCR5 cells were collected and diluted in DMEM (10% FBS) to 100,000 cells ml 21 and added to the pseudovirus/ inhibitor mixture. Cells were then incubated for 48 h at 37 uC. Viral entry was analysed using Britelite Plus (Perkin Elmer) and luciferase activity of cell lysates was read using a Victor X3 plate reader (Perkin Elmer).
HIV-1 neutralization assays. GHOST-CCR5 or -CXCR4 cells were plated into 12-well plates at 50,000 cells per well. HIV-1 pseudovirus was diluted in RPMI and titrated amounts of CD4-Ig, fusion1, fusion2 or eCD4-Ig were added. Virus and inhibitor were incubated at room temperature for 20 min and added to the cells for 2 h at 37 uC. Cells were then washed with serum-free medium and then incubated in 1 ml of DMEM (10% FBS) for 48 h at 37 uC. Cells were collected by trypsinization, fixed in 1% paraformaldehyde in PBS, and viral entry was determined by flow cytometry based on GFP expression.
For studies of infectious virus, unstimulated PBMCs were collected and resuspended in RPMI medium (15% FBS, 20 U ml 21 IL-2). Cells were plated in a 12-well plate at 10 6 cells per well. HIV-1 was diluted in RPMI and varying amounts of inhibitor were added. The virus and inhibitor was incubated at room temperature for 20 min and added to the cells for 3 h at 37 uC. Cells were then washed with serumfree medium and resuspended in fresh RPMI medium (15% FBS, 20 U ml 21 IL-2). At 3-day intervals after infection, supernatants were collected and fresh RPMI medium (15% FBS, 20 U ml 21 IL-2) was added to the cells. Supernatants were analysed for viral infection by ELISA with Alliance HIV-1 p24 antigen ELISA kit (Perkin Elmer).
TZM-bl neutralization assays were performed as previously described 42 . In brief, HIV-1 pseudoviruses were pre-incubated with titrated amounts of CD4-Ig or eCD4-Ig variants in DMEM (10% FBS) for 1 h at 37 uC. TZM-bl cells were collected and diluted in DMEM (10% FBS) to 100,000 cells ml 21 and added to the pseudovirus/ inhibitor mixture. Cells were then incubated for 48 h at 37 uC. Viral entry was analysed using Britelite Plus (Perkin Elmer) and luciferase activity was read using a Victor X3 plate reader (Perkin Elmer). All neutralization and enhancement studies of Figs 1-4 were performed at least twice in triplicate. All error bars represent s.e.m. Antibody-dependent cell-mediated cytotoxicity assays. ADCC activity was performed as previously described 43 . In brief, CEM.NKR CCR5 CD4 1 T cells were infected 4 days with infectious HIV-1 NL4.3, SHIV-KB9 or SIVmac239. After 4 days, KHYG-1 effector cells were co-incubated with infected cells in the presence of titrated CD4-Ig, eCD4-Ig variants, or the b12 antibody for 8 h. ADCC activity was measured by luciferase activity as above. Production of HIV-1 NL4-3 stocks and SHIV-AD8-EO stocks for in vivo studies. A molecular clone of HIV-1 NL4-3 was obtained from the AIDS Research and Reference Reagent Program (ARRRP), Division of AIDS, NIAID, NIH from material deposited by S. Gartner, M. Popovic, R. Gallo and M. Martin. Virus stocks were produced in 293T cells by transient transfection using TurboFect (Thermo Scientific) and 12 mg of proviral plasmid. Supernatants were collected at 40 h, filtered through 0.45-mm filters, and dispensed into single use doses and frozen at 280 uC. Viruses were quantified by p24 ELISA (Zeptometrix) and by GHOST cell titer 44 to determine infectious units per millilitre (IU ml 21 ). Titering was performed per the GHOST cell line protocol obtained through ARRRP. The molecular clone of SHIV-AD8-EO was a gift from M. Martin 45 . 293T cells were plated in 140 mm flasks and transfected with 80 mg DNA per plate by calcium phosphate technique. At 12 h after transfection, flasks were replaced with fresh DMEM (10% FBS). Medium was collected at 48 h after transfection, frozen at 280 uC, and titred using an SIV p27 ELISA kit (ABL). Haematopoietic stem cell isolation and NSG mouse transplantation. Human CD34 1 haematopoietic stem cells were isolated from fetal livers obtained from Advanced Bioscience Resources, INC (ABR). Tissue was disrupted and incubated with 1 mg ml 21 collagenase/dispase (Roche Applied Sciences) for 15 min at 37 uC. Cells were isolated by passing the disrupted tissue through a 70-mm filter. Red blood cells were lysed in BD Pharm Lyse (BD Biosciences), with CD34 1 cells being isolated using CD34 MACS microbeads (Miltenyi) according to manufacturer's instructions with an additional purification step using a second column. NOD.Cg-Prkdc scid Il2rc tm1Wj/Szj (NOD/SCID/Il2rg 2/2 , NSG) mice were obtained from Jackson Laboratories. Neonatal mice received 150 cGy radiation, and 2-4 h later 1 3 10 6 CD34 1 haematopoietic stem cells in 1% heparin (Celgene) via intrahepatic injection. Mice were monitored for engraftment levels of human CD45 1 cells and development of T cells and B cells at 8, 10 and 12 weeks after engraftment. Mouse infections, treatment and analysis. Humanized mice with evidence of human CD4 1 T-cell development in blood were infected with 5 3 10 4 IU of HIV-1NL4.3 by intraperitoneal injection. Mice were administered with 65 mg of eCD4-Ig once weekly for the first 2 weeks, starting at 8 days before the HIV-1 challenge, and then twice weekly starting at week 3 by retro-orbital injection while under anaesthetization by 2.5% isoflurane. Mock-treated mice received a retro-orbital injection of PBS 1 and 8 days before HIV-1 challenge, and were anaesthetized in parallel with eCD4-Ig mice throughout. Every week after infection the mice were anaesthetized by inhalation of 2.5% isoflurane and blood was collected retro-orbitally for analysis. At week 6, three eCD4-Ig-treated mice and one mock-treated mouse (who had not become infected) were challenged a second time with 5 3 10 4 IU HIV-1 NL4-3. Mouse blood was blocked for 20 min at room temperature in FBS (Denville) and stained with appropriate antibodies for 15 min at room temperature. Red blood cells were removed by incubation in BD FACS Fix/Lysing Solution (BD Biosciences), which was removed by dilution with PBS before analysis by flow cytometry. HIV-1 levels in peripheral blood were determined by extracting viral RNA from mouse plasma at each blood draw using a viral RNA isolation kit (Qiagen) followed by Taqman One-Step RT-PCR (Life Technologies) using a primer and probe set targeting the HIV-1 LTR region, as previously described 46, 47 . Reactions were performed and analysed using a 7500 Fast Realtime PCR System (Life Technologies).
To analyse engrafted T cells by flow cytometry, stained cells were acquired on a FACS Canto II (BD Biosciences) and analysed using FlowJo software v7.6.5 (Tree Star Inc.). Blood samples were stained using human-specific antibodies at a 1:20 dilution for CD4-V450 (RPA-T4), CD8-APC (RPAT8), CD3-PE (UCHT1) and CD45-PerCP (TUI16) (BD Bioscience). Up to 10,000 events were recorded for viable cell populations and gated based on fluorescence minus one controls as previously described 46 . All mouse studies were performed in accordance with the Scripps Research Institute Institutional Review Board, protocol number 14-018. No statistical methods were used to predetermine sample size. AAV inoculation of rhesus macaques. Eight 4-year-old AAV1-negative male Indian-origin rhesus macaques were housed at the New England Primate Research Center in accordance with standards set forth by the American Association for Accreditation of Laboratory Animal Care. Their weights at the time of AAV inoculation ranged from 5.2 to 8.2 kg. Macaques were separated into age-and weightmatched control groups, but blinding and randomization were not performed. Four macaques were inoculated with 1 ml RPMI containing 2.5 3 10 13 AAV1 particles delivering 80% of a single-strand rh-eCD4-Ig transgene (IgG2 isotype) and 20% of a single-strand rhesus TPST-2 transgene into each quadriceps muscle (two 0.5 ml per injections per quadriceps muscle). Five millilitres of sera was obtained every 1-2 weeks after AAV inoculation beginning at week 4. Animals were challenged at week 8 after inoculation with 2 pg p27 of SHIV-AD8-EO. SHIV-negative animals were repeatedly challenged with escalating doses of SHIV-AD8-EO up to 800 pg p27. Plasma viral loads were quantified as previously described 45 .
For AAV studies of bNAbs, six 2-year-old AAV1-negative Indian-origin rhesus macaques (two males and four females) were housed at the New England Primate Research Center in accordance with standards set forth by the American Association for Accreditation of Laboratory Animal Care. Three macaques were inoculated with 1 ml RPMI containing 1 3 10 13 AAV1 particles delivering single-strand rh-3BNC117-IgG2 transgene into one quadriceps (two 0.5-ml injections) and 1 ml RPMI containing 1 3 10 13 AAV1 particles delivering single-stranded rh-10-1074-IgG2 transgene into the contralateral quadriceps (two 0.5-ml injections). The other three macaques were inoculated with 1 ml RPMI containing 1 3 10 13 AAV1 particles delivering single-strand rh-NIH45-46-IgG2 transgene into one quadriceps (two 0.5-ml injections) and 1 ml RPMI containing 1 3 10 13 AAV1 particles delivering single-strand rh-PGT121-IgG2 transgene into the contralateral quadriceps (two 0.5-ml injections). Five millilitres of sera was obtained every 2 weeks beginning at week 2 and analysed by ELISA. All primate studies were performed in accordance with the Harvard Medical School Standing Committee on Animals protocol number 04888. eCD4-Ig, rh-eCD4-Ig and anti-transgene antibody concentrations in NSG mice and rhesus macaque sera. In vivo concentrations of eCD4-Ig, rh-eCD4-Ig were measured by ELISA as previously described 2 . In brief, to measure NSG mouse and macaque serum concentrations, ELISA plates (Costar) were coated with 5 mg ml 21 SIV gp120 overnight at 4 uC. Plates were washed with PBS-T (PBS plus 0.05% Tween-20) twice and blocked with 5% milk in PBS for 1 h at 37 uC. Sera serially diluted in 5% milk in PBS were added to the plate and incubated for 1 h at 37 uC. Samples were washed five times with PBS-T and a horseradish peroxidase secondary antibody (Jackson Immuno Research) recognizing human IgG1. Plates were incubated for 1 h at 37 uC and then washed ten times with PBS-T. TMB solution (Fisher) was added for 10 min at room temperature and then stopped with TMB Stop Solution (Southern Biotech). Absorbance was read at 450 nm by a Victor X3 plate reader (Perkin Elmer) and compared with a standard curve generated using a rh-eCD4-Ig mixed with pre-inoculation sera. Anti-rh-eCD4-Ig antibodies and anti-bNAb antibodies were measured in the same way except that ELISA plates were coated with 5 mg ml 21 of various constructs. Constructs so assayed included rh-eCD4-Ig, rh-CD4-Ig I39N , rh-CD4-Ig domains 1 and 2 (with or without Ile39Asn) bearing a human IgG1 Fc and hinge domain, C-terminal CCR5mim2-Ig (human IgG1 Fc and hinge, no CD4 domains), NIH45-46 bearing the rhesus IgG2 Fc domain and hinge, or HIV-1 bNAbs. Serum samples were diluted 10-or 20-fold and blocked in 5% milk in PBS. Anti-transgene antibodies were measured using secondary antibodies detecting either the kappa or lambda light chain (Southern Biotech) that was opposite of the antibody being assayed when comparing the anti-bNAb response to that to rh-eCD4-Ig. Both anti-kappa and anti-lambda secondary antibodies were used when measuring anti-rh-eCD4-Ig responses alone. TMB solution was added for 10-15 min at room temperature and measured as described above.
Extended Data Figure 2 | Additional characterization of eCD4-Ig. a, b, Experiments similar to those of Fig. 1b except that CD4-Ig (red), fusion1 (grey), fusion2 (green) and fusion3 (eCD4-Ig; blue) are compared using HIV-1 pseudotyped with the envelope glycoproteins of the 89.6 (a) or ADA (b) isolates. c, d, Experiments similar to those in Fig. 1e except that CD4-Ig (red), eCD4-Ig (blue) or heterodimers thereof (grey) are compared. e, CD4-Ig, eCD4-Ig and the CD4-Ig/eCD4-Ig heterodimer assayed in c, d and Fig. 1e were analysed by SDS-PAGE and stained with Coomassie blue under reducing (left) and non-reducing (right) conditions. f, g, Infectious 89.6 (f) or SG3 (g) HIV-1 was incubated with human PBMC in the presence of the indicated concentrations of CD4-Ig (red) or eCD4-Ig (blue), or without either inhibitor (grey). Culture supernatants were collected on the indicated day and viral p24 levels were measured by ELISA. h, Viral loads in RNA copies ml 21 are shown for each humanized mouse of Fig. 1f . Mice treated with eCD4-Ig are indicated with blue lines and mice treated with PBS are indicated with red lines. The 800 copies ml 21 limit of detection of this assay is indicated by a dashed line. Experiments in a-g were performed at least twice with similar results. Error bars denote s.e.m. of triplicates.
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Extended Data Figure 3 | A model of eCD4-Ig bound to the HIV-1 Env trimer. a, The structure (2QAD) of gp120 (YU2 isolate) bound to the tyrosinesulfated CD4i antibody 412d and CD4 domains 1 and 2 (ref. 10) , was fitted into a cryoelectron micrograph of the HIV-1 envelope glycoprotein trimer (Env; Bal isolate) bound to CD4 (ref. 48 ). gp120 and CD4 domains 1 and 2 are shown in blue and red, respectively. 412d sulfotyrosines are represented as green (carbon), red (oxygen) and yellow (sulphur) spheres. The remainder of 412d was excluded for clarity. b, The same structure shown in a rotated 90u about the horizontal axis. Note that the sulfotyrosine-binding pockets are proximal to the trimer axis, whereas the C terminus of CD4 domain 2 is distal from the trimer axis, preventing both CD4 domains of CD4-Ig from simultaneously binding the same Env trimer. c, A model of how eCD4-Ig may associate with Env is presented. The Fc domain of human IgG1 (1FCC, cyan) 49 was positioned to be proximal to the gp120 sulfopeptide-binding pocket occupied by sulfotyrosine 100 (Tys 100) of the 412d heavy chain while avoiding steric interaction with Env. Tys 100 occupies a pocket in gp120 thought to bind CCR5 sulfotyrosine 10 (ref. 50 ). This pocket is also critical for binding of CCR5mim1 and CCR5mim 2 (refs 20, 22) . In this model, the Fc domain is oriented to allow each eCD4-Ig sulfopeptide to engage a different gp120 protomer 24 . A single CD4 domain also binds one of the sulfopeptide-bound protomers. Distances between the C terminus of CD4 and the N terminus of one Fc domain monomer (38.1 Å ), between the C terminus of the Fc domain and Tys 100 pocket of the CD4-bound gp120 protomer (30.6 Å ), and between the C terminus of the Fc domain and Tys 100 pocket of an adjacent gp120 protomer (33.3 Å ), are indicated. d, Residues not visible in the crystal structures used to construct this model are shown between brackets. In the model shown in c, these residues span the distances indicated. Note that these distances are well under the extension of a typical beta strand. CD4-, IgG1-and CCR5mim1derived residues are shown in red, cyan, and green, respectively, with linker regions shown in black. Residues visible in the crystal structures, including the CCR5mim1 sulfotyrosine presumed to fill the Tys 100 pocket, are highlighted in grey. Modelling was performed using UCSF Chimera version 1.8.
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Extended Data Figure 6 | Further comparison of eCD4-Ig and HIV-1 neutralizing antibodies. a, IC 90 values for the same experiments shown in Fig. 2a , presented in the same format. b, Numeric IC 50 and IC 90 values of the experiment shown in a and Fig. 2a are shown, using the same colour coding of Extended Data Figs 4 and 5. The s.e.m. of triplicates are indicated below their IC 50 and IC 90 values. c, Experiments similar to those in Fig. 2b except that HIV-1 pseudotyped with the Env of the HIV-2 isolate ST was incubated with the indicated concentrations of CD4-Ig, eCD4-Ig variants or the CD4bs antibodies IgG-b12, VRC01 or NIH45-46. Error bars denote s.e.m. of triplicates.
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